Bioanalytical services
Celerion provides regulated bioanalytical services across all phases of drug development. Its capabilities include LC-MS/MS, ligand-binding assays, PK/ADA testing, cell-based assays, biomarkers, flow cytometry, qPCR, ELISpot, PBMC isolation, metabolite profiling, and dose formulation analysis.
This breadth of expertise allows Celerion to tailor the analytical approach to the program, while giving sponsors access to both established and advanced technologies within one global organization.
Gyrolab systems and applications
Celerion currently operates two Gyrolab xPand Systems, both in use for more than a year. On the Gyrolab platform, the team supports a range of assay types, including:
- PK assays
- PD and biomarker assays
- Immunogenicity assays
- Antibody pair screening as assay reagents
Gyrolab is particularly well suited to large molecule bioanalysis, where speed, sensitivity, low sample consumption, and broad dynamic range are critical to program success. Celerion also sees Gyrolab as an important platform in its continued growth in large molecule bioanalysis, including future expansion of immunoassay capabilities.
Key advantages of Gyrolab
For Celerion, one of the biggest strengths of Gyrolab is the ability to do more with less. Automation reduces manual effort, while nanoliter-scale sample requirements help conserve valuable study material. Faster method development and validation, plus the ability to run overnight with multiple CDs, also contribute to higher capacity and shorter timelines.
Celerion also highlights the platform’s fast column flow-through as a practical advantage in challenging biological matrices, helping address selectivity issues that can be more difficult with plate-based technologies relying on longer incubations. Broad dynamic range and strong reproducibility help minimize repeat analyses, supporting both cost efficiency and data reliability.
When Gyrolab Is a platform of choice
Gyrolab is a preferred platform for Celerion when speed, efficiency, and data quality are especially important. The team notes that methods can often be developed up to three times faster than on other immunoassay platforms because the workflow is much shorter than with manual methods. That makes Gyrolab especially valuable when timelines are compressed.
The platform is also a strong fit when sample volume is limited, when higher throughput is needed, and when sponsors want to reduce variability while moving programs forward with confidence. For PK, PD, biomarker, and immunogenicity applications, Gyrolab helps Celerion provide precise, scalable solutions aligned with the demands of modern drug development.
A global, integrated approach
Celerion’s investment in Gyrolab reflects a broader commitment to combining scientific expertise, regulatory credibility, and innovative technologies. By integrating Gyrolab into a wider suite of analytical capabilities, including LC-MS/MS, high-resolution mass spectrometry, cell-based assays, and advanced biomarker technologies, Celerion is able to support faster and more informed decision-making across discovery, first-in-human studies, late-phase trials, and biosimilar development.
The company also emphasizes the importance of experienced scientific teams in unlocking the value of the platform. For Celerion, Gyrolab is not simply an instrument, but part of a global strategy to deliver efficient, compliant, and insightful bioanalysis from discovery through late-stage clinical development.
Company description
Celerion is a global provider of clinical and bioanalytical services focused on accelerating drug development through regulatory-ready science. Its laboratories in Lincoln, Nebraska and Zurich, Switzerland support a wide range of programs spanning small molecules, biologics, biosimilars, biomarkers, and cell and gene therapies. The company combines scientific depth with advanced analytical technologies to generate PK/PD, immunogenicity, and metabolite data that support critical development decisions.
With integrated clinical expertise and a broad platform portfolio, Celerion supports sponsors from early development through later-stage studies with the speed, confidence, and technical rigor needed in modern bioanalysis.
Talk to Celerion
Looking for a CRO partner with global reach, strong regulated bioanalytical expertise, and proven Gyrolab experience? Celerion offers scalable support for PK, PD, biomarker, and immunogenicity programs with the speed and quality needed for today’s development timelines.
Contact Celerion
